Friday, May 06, 2016 8:33:29 AM
Was more like 338% off a low base
Using the 1Q/13 - 3Q/13 quarterlies and the full-year 2013 revenues, I calculated the 4Q/13 revenues and compared them to those of 1Q/14.
If we assume that there were no changes to 1Q - 3Q when audited, then 4Q/13 revenues were only $25.7K, down 50% from the previous quarter.
With 1Q/14 revs of $112.4K, DEWM saw a 338% sequential quarter increase in revenue, but it was off a very low base. Compared to 1Q/13, revenues were up 42%.
One other thing to note is that IIRC, Moran was talking about revenue from LEAN. Therefore, it's possible that LEAN alone could have seen sequential growth greater than 338%, perhaps even the claimed 540% - 550%.
Of course, the FDA letter was sent to DEWM just a few days before 1Q/14 ended, so it would be interesting to see the 2Q/14 and 3Q/14 revenues.
He probably wasn't lying, but without mentioning the decline in 4Q/13, was being disingenous. Then again, a lot of companies do this when they report percentage growth.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM